Click Here for 5% Off Your First Aladdin Purchase!

Etrolizumab (anti-α4β7), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to Integrin α4β7, >95%, high purity, Human IgG1, Inhibitor of integrin α4β7;Antibody of integrin; alpha 7 subunit;Antibody of integrin αEβ7

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Application: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
  • Species reactivity(Reacts with): Human
  • Isotype: Human IgG1
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab170530
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab170530-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$119.90
Ab170530-1mg
1mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$567.90
Ab170530-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$1,017.90
Ab170530-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,797.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameEtrolizumab (anti-α4β7), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to Integrin α4β7, >95%, high purity, Human IgG1
SynonymsAntigen CD49D antibody; CD49d antibody; IA4 antibody; Integrin alpha 4 subunit antibody; Integrin alpha IV antibody; Integrin beta 7 antibody; Integrin beta 7 subunit antibody; ITGA4 antibody; ITGB7 antibody; LPAM1 antibody; 269C wild type; CD49 antigen-l
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityIntegrin α4β7
ApplicationELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeANTAGONIST
Mechanism of actionInhibitor of integrin α4β7;Antibody of integrin; alpha 7 subunit;Antibody of integrin αEβ7
Product Description

Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD).

Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Antibody TypePrimary antibody
ClonalityRecombinant
IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE27.0 kDa (Light Chain) & 51.3 kDa (Heavy Chain), under reducing conditions; 177.9 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
SourceCHO supernatant
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1044758-60-2

Associated Targets

ITGA4 Tclin Integrin alpha-4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ITGB7 Tclin Integrin beta-7 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ITGA7 Tbio Integrin alpha-7 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot NumberCertificate TypeDateItem
ZJ23F1001296Certificate of AnalysisOct 13, 2023 Ab170530
ZJ23F1001297Certificate of AnalysisOct 13, 2023 Ab170530

Related Documents

References

1. Schön MP, Arya A, Murphy EA, Adams CM, Strauch UG, Agace WW, Marsal J, Donohue JP, Her H, Beier DR et al..  (1999)  Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice..  J Immunol,  162  (11): (6641-9).  [PMID:10352281]
2. Hu MC, Crowe DT, Weissman IL, Holzmann B.  (1992)  Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing..  Proc Natl Acad Sci USA,  89  (17): (8254-8).  [PMID:1518854]
3. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S et al..  (2005)  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin..  N Engl J Med,  352  (24): (2499-507).  [PMID:15958805]
4. Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, Strauch U, Burgess G, Spanton J, Martin SW et al..  (2011)  The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study..  Gut,  60  (8): (1068-75).  [PMID:21317177]
5. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S et al..  (2013)  Vedolizumab as induction and maintenance therapy for ulcerative colitis..  N Engl J Med,  369  (8): (699-710).  [PMID:23964932]
6. Holzmann B, McIntyre BW, Weissman IL.  (1989)  Identification of a murine Peyer's patch--specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha..  Cell,  56  (1): (37-46).  [PMID:2463092]
7. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A et al..  (2014)  Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial..  Lancet,  384  (9940): (309-18).  [PMID:24814090]
8. Karecla PI, Bowden SJ, Green SJ, Kilshaw PJ.  (1995)  Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7)..  Eur J Immunol,  25  (3): (852-6).  [PMID:7705417]
9. Cepek KL, Parker CM, Madara JL, Brenner MB.  (1993)  Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells..  J Immunol,  150  (8 Pt 1): (3459-70).  [PMID:8468482]

Solution Calculators